Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin Reimbursement Worry Drives Patient Petition To FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Fueled by a teen on Facebook whose mom has breast cancer, grassroots campaign aims to keep Avastin as a treatment option, but NCCN may carry as much weight as FDA.

You may also be interested in...



Roche Gets Reprieve On Avastin For Breast Cancer With Delay At FDA

FDA extends user fee date in lieu of reaching decision on whether or not to pull the breast cancer approval for bevacizumab.

Roche Gets Reprieve On Avastin For Breast Cancer With Delay At FDA

FDA extends user fee date in lieu of reaching decision on whether or not to pull the breast cancer approval for bevacizumab.

Pfizer Pulls Mylotarg For Safety 10 Years After Accelerated Approval

Although Pfizer's voluntary withdrawal of its acute myeloid leukemia therapy Mylotarg is the first complete withdrawal of an accelerated approval NDA, but as in other cases where the confirmatory trial fails to substantiate the initial signs of efficacy that supported the accelerated approval, FDA is not completely closing the door on access to the drug

Topics

UsernamePublicRestriction

Register

PS071063

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel